CIK 0001048477
- Large accelerated filer
BIOMARIN PHARMACEUTICAL INC
Sign in to watch- Ticker
- BMRN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 680397820
- Phone
- +1 415-506-6700
- Business address
- 105 DIGITAL DRIVE, NOVATO, CA, 94949
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,466,459
- in 2 filings
Net −$1,466,459. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-04-18 | BIENAIME JEAN JACQUES Chief Executive Officer | Sale | −20,000 | $81.91 | $1.6M | 334,983 |
| 2022-04-18 | BIENAIME JEAN JACQUES Chief Executive Officer | Exercise or conversion · Stock Option (Right to buy Common Stock) | −20,000 | 55,000 | ||
| 2022-04-14 | BIENAIME JEAN JACQUES Chief Executive Officer | Exercise or conversion | +10,000 | $37.46 | $375K | 344,983 |
| 2022-04-14 | BIENAIME JEAN JACQUES Chief Executive Officer | Sale | −10,000 | $83.66 | $837K | 334,983 |
| 2022-04-14 | BIENAIME JEAN JACQUES Chief Executive Officer | Exercise or conversion · Stock Option (Right to buy Common Stock) | −10,000 | 75,000 | ||
| 2022-04-14 | LAWLIS V BRYAN Director | Exercise or conversion | +4,250 | $37.46 | $159K | 28,220 |
| 2022-04-14 | LAWLIS V BRYAN Director | Sale | −4,250 | $83.66 | $356K | 23,970 |
| 2022-04-14 | LAWLIS V BRYAN Director | Exercise or conversion · Stock Option (Right to buy Common Stock) | −4,250 | 0 | ||
| 2022-04-13 | Ajer Jeffrey Robert EVP, Chief Commercial Officer | Sale | −1,180 | $82.47 | $97K | 55,077 |
| 2022-03-30 | Ajer Jeffrey Robert EVP, Chief Commercial Officer | Sale | −1,381 | $79.56 | $110K | 56,257 |
| 2022-03-29 | Ajer Jeffrey Robert EVP, Chief Commercial Officer | Sale | −1,618 | $79.43 | $129K | 57,638 |
| 2022-03-23 | Ajer Jeffrey Robert EVP, Chief Commercial Officer | Sale | −6,129 | $81.78 | $501K | 59,256 |
| 2022-03-22 | Ajer Jeffrey Robert EVP, Chief Commercial Officer | Sale | −2,073 | $81.00 | $168K | 65,385 |
| 2022-03-21 | Davis George Eric EVP, General Counsel | Sale | −6,129 | $81.29 | $498K | 63,329 |
| 2022-03-16 | FUCHS HENRY J President, Worldwide R&D | Shares withheld for taxes | −2,259 | $80.72 | $182K | 143,753 |
| 2022-03-16 | Mueller Brian EVP, Chief Financial Officer | Shares withheld for taxes | −582 | $80.72 | $47K | 38,299 |
| 2022-03-16 | Davis George Eric EVP, General Counsel | Shares withheld for taxes | −1,252 | $80.72 | $101K | 69,458 |
| 2022-03-16 | BIENAIME JEAN JACQUES Chief Executive Officer | Shares withheld for taxes | −5,560 | $80.72 | $449K | 334,983 |
| 2022-03-16 | Ajer Jeffrey Robert EVP, Chief Commercial Officer | Shares withheld for taxes | −1,287 | $80.72 | $104K | 67,458 |
| 2022-03-15 | FUCHS HENRY J President, Worldwide R&D | Grant or award | +38,790 | 158,113 |
Page 24 of 36 · 707 trades